Agree, positive result,
Slightly lower NPAT, only because of reinvestment into capital is good news,
And good to see growth plan moving away from the Aqua products, makes sense to capitalise on their products that work.
Would've been nice to see a bit more revenue growth, but with the realigned growth plan it opens up 2025 and 2026 to improved numbers.
- Forums
- ASX - By Stock
- RIC
- Ann: FY24 Full Year Results Investor Presentation
Ann: FY24 Full Year Results Investor Presentation, page-6
Featured News
Add RIC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$2.74 |
Change
0.040(1.48%) |
Mkt cap ! $865.3M |
Open | High | Low | Value | Volume |
$2.72 | $2.75 | $2.68 | $866.1K | 319.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 2274 | $2.72 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$2.76 | 13349 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 200 | 2.650 |
1 | 1490 | 2.620 |
1 | 770 | 2.600 |
1 | 780 | 2.560 |
1 | 4166 | 2.520 |
Price($) | Vol. | No. |
---|---|---|
2.760 | 11075 | 2 |
2.770 | 1000 | 1 |
2.790 | 215 | 1 |
2.800 | 55000 | 2 |
2.810 | 5000 | 1 |
Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
Featured News
RIC (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online